The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Arrowhead Pharmaceuticals; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Calithera Biosciences; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; Idera; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Sanofi; Scholar Rock; Seagen; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Sandra J. Lee
Employment - NantWorks (I)
Stock and Other Ownership Interests - NantWorks (I)
Consulting or Advisory Role - Roche/Genentech
 
Bartosz Chmielowski
Consulting or Advisory Role - Deciphera; Epizyme; Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; OncoSec; Sanofi
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Deciphera; Epizyme; Regeneron
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris; PACT Pharma
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Appia Bio; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; Highlight Therapeutics; ImaginAb; Isoplexis; Kite/Gilead; Lutris; MapKure; Merus; PACT Pharma; Pluto Immunotherapeutics; RAPT Therapeutics; Rgenix; Synthekine; Tango Therapeutics
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Non-viral gene editing to Arsenal Bio
 
Ahmad A. Tarhini
Consulting or Advisory Role - Array BioPharma; BioNTech; Bristol-Myers Squibb; Clinigen Group; Eisai; Genentech/Roche; Immunocore; Merck; Novartis; Partner Therapeutics; Pfizer/EMD Serono; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); Merck (Inst); OncoSec (Inst); Sanofi/Regeneron (Inst)
 
Thach-Giao Truong
No Relationships to Disclose
 
Diwakar Davar
Honoraria - Array BioPharma; Immunocore; Instil Bio; Merck; Tesaro; Vedanta Biosciences
Consulting or Advisory Role - Instil Bio; Shionogi (I); Vedanta Biosciences
Research Funding - Bristol-Myers Squibb; CellSight Technologies; Checkmate Pharmaceuticals; medpacto; Merck; Tesaro; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231
 
Mark Allen O'Rourke
No Relationships to Disclose
 
Brendan D. Curti
Honoraria - Clinigen Group; Nektar
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Galectin Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
Travel, Accommodations, Expenses - Agonox
 
Joanna M. Brell
No Relationships to Disclose
 
Kari Lynn Kendra
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Alexandra Ikeguchi
No Relationships to Disclose
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Apricity Therapeutics; Arsenal IO; Beigene; Georgiamune; Imvaq Therapeutics; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; Trieza Therapeutics
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Apricity Therapeutics; Arsenal IO; Ascentage Pharma; Astellas Pharma; AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo,Inc; Dragonfly Therapeutics; F-Star Biotechnology; Georgiamune; Idera; Imvaq Therapeutics; Kyowa Kirin Pharmaceutical; Lilly; Maverick Therapeutics; Merck; PsiOxus Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Sellas Life Sciences; Surface Oncology; Tizona Therapeutics, Inc.; Trishula Therapeutics; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2; Engineered Vaccinia Viruses for Cancer Immunotherapy; I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells.; I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer; I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.; I am co-inventor and receive royalties for a patent for immune modulating antibodies.; RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; AXIO Research; Bristol-Myers Squibb; Checkmate Pharmaceuticals; DermTech; Elsevier; Harbour BioMed; Immunocore; Iovance Biotherapeutics; Istari Oncology; Natera; Novartis; Oncocyte; OncoSec; Pfizer; Scopus BioPharma; Takeda
Speakers' Bureau - BMS
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)